NICE Recommends Vutrisiran for NHS Use in Transthyretin Amyloid Cardiomyopathy
the National Institute for Health adn Care Excellence (NICE) has recommended vutrisiran for routine use within the National Health Service (NHS) in England. This approval provides a new, disease-modifying treatment option for adults diagnosed with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). Vutrisiran will be available alongside tafamidis, offering patients increased choices in managing this challenging condition.
ATTR-CM is a progressive and ofen fatal disease caused by the buildup of abnormal amyloid protein in the heart. This buildup stiffens the heart muscle, leading to heart failure and other serious complications.Until recently, treatment options were limited, primarily focusing on symptom management.
Vutrisiran, developed by Alnylam Pharmaceuticals, is an RNA interference (RNAi) therapy. It works by reducing the production of transthyretin (TTR), the protein that forms the amyloid deposits. By lowering TTR levels, vutrisiran aims to slow or halt the progression of the disease. Clinical trials have demonstrated vutrisiran’s ability to improve functional capacity and quality of life for individuals with ATTR-CM.
Tafamidis, the other approved disease-modifying therapy, functions differently. It stabilizes TTR, preventing it from disassembling and forming amyloid fibrils. The availability of both vutrisiran and tafamidis allows clinicians to tailor treatment strategies to individual patient needs and characteristics.
NICE’s decision follows a thorough evaluation of clinical trial data and cost-effectiveness analyses. The recommendation signifies a significant step forward in the care of patients with ATTR-CM, offering hope for improved outcomes and a better quality of life. Patients and healthcare professionals can find further information on the NICE website and through their cardiologists.
Publication Date: 2025/11/23 13:18:04
Sources:
Keep reading